Therapeutic Plasma Exchange as Management of Complicated Systemic Lupus Erythematosus and Other Autoimmune Diseases

Table 4

TPE indications and outcomes.

TPE indication/Outcome	Improvement, N. patients (%)	Unchanged, N. patients (%)	Worsening, N. patients (%)	Total	Death, N. patients (%)	Dialysis
DAH	11 (55)	2 (10)	7 (35)	20	7 (35)	3 (15)
Neuropsychiatric SLE	7 (78)	1 (11)	1 (11)	9	1 (11)	1 (11)
RPGN	5 (71)	2 (29)	0	7	0	3 (60)
CAPS	4 (80)	0	1 (20)	5	1 (20)	0
Thrombotic microangiopathy	2 (40)	1 (20)	2 (40)	5	2 (40)	1 (20)
Lupus Nephritis	2 (50)	2 (50)	0	4	0	2 (50)
Lupus severe skin involvement	3 (100)	0	0	3	0	0
Inflammatory myopathies	1 (33)	1 (33)	1 (33)	3	1 (33)	0
Optic Neuromyelitis	1 (100)	0	0	1	0	0
Severe scleroderma	0	1 (100)	0	1	0	0
Evans Syndrome	0	1 (100)	0	1	0	0
Insulin resistance type B	1 (100)	0	0	1	0	0
Legs vasculitis	1 (100)	0	0	1	0	0
CNS Vasculitis	1 (100)	0	0	1	0	0
Gastrointestinal lupus	0	1 (100)	0	1	0	0
Autoimmune meningoencephalitis	1 (100)	0	0	1	0	0
Severe SLE	1 (100)	0	0	1	0	0
Acute allograft rejection	0	1 (100)	0	1	0	1 (100)

TPE: therapeutic plasma exchange; DAH: diffuse alveolar hemorrhage; SLE: systemic lupus erythematosus; RPGN: rapidly progressive glomerulonephritis CAPS: catastrophic antiphospholipid syndrome; CNS: central nervous system.